Logo

Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar- tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis

Share this
Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar- tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis

Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar- tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis

Shots:

  • Bio-Thera to receive $30M up front following the achievement of P-III satisfactory results and is eligible for commercial milestones along with royalties. The transaction is expected to close in Q2’21
  • Biogen to get exclusive regulatory- manufacturing- and commercial rights of BAT1806 in all countries excluding China (includes Hong Kong- Macau- and Taiwan)
  • Biogen will expand its global biosimilars footprint with the potential approval of BAT1806 is a P-III clinical stage IL-6 receptor mAb that is a proposed biosimilar referencing Actemra (tocilizumab)

  Ref: GlobeNewswire | Image: Biogen

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions